03/13/2024
KVK Reaches Global Resolution of DOJ Litigation
PR NewswireMon, Feb 26, 2024. 2 min read NEWTOWN, Pa., Feb. 26, 2024 /PRNewswire/ — KVK Tech, Inc. (“KVK”), announced today that it has resolved all matters involving the U.S. Attorney’s Office for the Eastern District of Pennsylvania (EDPA) and the Consumer Protection Branch of the Department of Justice, including US v . Vepuri, et al. The government charged KVK… Read more »
09/29/2023
KVK-Tech, Inc. Issues Voluntary Nationwide Recall of one lot of Betaxolol Tablets, USP 10 mg (Batch Number: 17853A) as a precautionary measure due to a single foreign tablet found during the line clearance after the batch was packaged
Name: Susan DiCroce, Senior Manager, Customer Service Phone Number: (215) 579-1842 Ext: 1260 FOR IMMEDIATE RELEASE – 09/29/2023 – Newtown, Pennsylvania, KVK-Tech, Inc. is voluntarily recalling one lot (Batch Number: 17853A; “the batch”) of Betaxolol Tablets, USP 10 mg, White, Round, film coated biconvex tablets, debossed “K” above bisect “13” on one side and plain… Read more »
04/18/2022
KVK is providing a gas subsidy check in April to all employees
Gas prices in the U.S. recently hit an all-time high and remain above $4 per gallon in many places across the country, and many KVK employees endure long commutes to work. In an effort to ease the financial burden of this global crisis for our employees, and in recognition of their hard work, KVK is providing a $500 gas… Read more »
03/23/2022
Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic
Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment HUNTINGTON, N.Y., March 22, 2022 /PRNewswire/ — Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination… Read more »
08/06/2021
KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5mL Due to Temperature Abuse
NEWTOWN, Pa., Aug. 6, 2021 /PRNewswire/ — Company Contact:Name: Susan DiCrocePhone Number: (215) 579-1842 Ext: 1260 KVK Tech, Inc., is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mL to the consumer level. The recall is based on customer complaints of unusual grittiness in the product, which KVK has determined was most probably caused by prolonged exposure… Read more »
06/11/2021
Press Release
The allegations attributed to KVK are without merit, and we intend to vigorously defend our company and its good name as this process moves forward. We will not comment further other than to say that the allegations relate to events that occurred a decade ago and at no time ever implicated product quality or patient… Read more »
07/15/2020
KVK is immensely proud of the dedication of our essential employees
At KVK, we realize that all that stands between the American public and a dangerous shortage of prescription medication are the men and women that make up the pharmaceutical industry. If these unsung-heroes do not make it to work, patients face dangerous drug shortages. KVK is immensely proud of the dedication of our essential employees…. Read more »
05/05/2018
1-2-3 Savings Program for Lomaira™
KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira™ (phentermine hydrochloride USP) 8 mg Tablets, CIV Cost Savings for Lomaira Patients NEWTOWN, PA., May 2, 2018 /PRNewswire/ — KVK Tech, Inc. (KVK), a leading American developer, manufacturer, and marketer of FDA-approved pharmaceuticals today announced the LOMAIRA 1-2-3 program. The 1-2-3 program allows patients to start… Read more »
11/14/2017
KVK Tech, Inc. Announces Partnership with Medix for International Expansion into Mexico.
KVK Tech, Inc. Announces Partnership with Medix for International Expansion into Mexico. NEWTOWN, PA., Nov 14, 2017 /PRNewswire/ — KVK Tech, Inc. (KVK), a leading American developer, manufacturer, and marketer of FDA-approved pharmaceuticals today announced a strategic partnership with Productos Medix S.A. de C.V. (“Medix”), a leader in pharmaceutical obesity products in Mexico. The licensing… Read more »
09/20/2016
KVK Tech Announces FDA-Approval of Lomaira™
KVK Tech Announces FDA-Approval of Lomaira™ (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up to Three Times Daily for Weight Reduction Newtown, PA, Sept. 20, 2016 — KVK Tech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Lomaira™ (phentermine hydrochloride USP) 8… Read more »
